Efficacy and Safety of Rivaroxaban versus Warfarin for the Treatment of Acute Pulmonary Embolism: A Real-World Study

BACKGROUND: Pulmonary embolism (PE) is a life-threatening disease. Target-specific anticoagulant rivaroxaban is a direct factor Xa inhibitor that can be safely used without laboratory monitoring. OBJECTIVE: To investigate the efficacy and safety of rivaroxaban versus warfarin for the treatment of ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yan, Duan, Linli, He, Wenjun, Hong, Cheng, Guo, Yehui, Wang, Xinni, Zhang, Nuofu, Chen, Yanghang, Wang, Tao, Wang, Jian, Liu, Chunli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7335399/
https://www.ncbi.nlm.nih.gov/pubmed/32676276
http://dx.doi.org/10.1155/2020/6813492

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7335399/
https://www.ncbi.nlm.nih.gov/pubmed/32676276
http://dx.doi.org/10.1155/2020/6813492

Ejemplares similares